Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 3

1.

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, Geho D, Middleton SA, Vassilev LT, Nichols GL, Bui BN.

Lancet Oncol. 2012 Nov;13(11):1133-40. doi: 10.1016/S1470-2045(12)70474-6.

PMID:
23084521
2.

Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.

Crago AM, Singer S.

Curr Opin Oncol. 2011 Jul;23(4):373-8. doi: 10.1097/CCO.0b013e32834796e6. Review.

3.

Pharmacological activation of wild-type p53 in the therapy of leukemia.

Kojima K, Ishizawa J, Andreeff M.

Exp Hematol. 2016 Sep;44(9):791-8. doi: 10.1016/j.exphem.2016.05.014. Review.

PMID:
27327543

Supplemental Content

Support Center